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Abstract 
Background 
Consumption of flavanol containing cocoa products has been shown to lower blood pressure (BP), 
but the minimum dose required to reduce BP is not known. This study aimed to examine the effect 
of three different doses of cocoa flavanols (CF) on 24-hour mean arterial blood pressure. 
Method 
Twenty four hour ambulatory blood pressure (24-ABP) monitoring was performed in 32 men and 
20 postmenopausal women with untreated mild hypertension (seated clinic BP >130/85 and 
<160/100 mmHg). Participants were randomised and instructed to consume daily a reconstituted 
cocoa beverage containing 33, 372, 712 or 1052 mg/d of CF for 6 weeks in a double-blind, parallel 
comparison. Seated clinic BP and 24 hr ABP were measured at 0, 3 and 6 weeks. 
Results 
Seated clinic BP did not change during the study period. There were significant reductions in 24-
hour systolic (5.3 ± 5.1 mmHg;  p = 0.001), diastolic (3 ± 3.2 mmHg;  p = 0.002) and mean arterial 
blood pressure (3.8 ± 3.2 mmHg;  p = 0.0004) at the 1052 mg/d CF only. No reduction in BP was 
seen at any other dose. 
Conclusion 
No evidence of dose response was seen in this experiment. The highest dose of 1052 mg CF/d was 
found to significantly lower BP. These results support previous evidence for CF to lower BP, 
however more research is needed to establish the most effective dose and food matrix. 
 3
Introduction 
Several intervention studies have reported beneficial effects of consuming cocoa containing 
products on blood pressure (BP) [1-5] and a recent meta-analysis confirmed this effect by 
demonstrating that the consumption of cocoa-rich foods for seven or more days has the capacity to 
lower resting BP in normotensive and mildly hypertensive adults [6]. This effect of cocoa products 
has been widely attributed to its content of flavanols and procyanidins (oligomeric and polymeric 
flavanols), which for the purpose of this paper will be included in the term “cocoa flavanols” (CF) 
[7, 8]. 
The recent meta-analysis [6] included five studies which compared the antihypertensive effects of 
CF-rich chocolate with chocolate containing few or no CF. The amount of chocolate consumed 
daily ranged from 46 to 105g and provided intakes of CF ranging from 246 to 500 mg/day. There 
was a mean BP reduction of 4.7 / 2.8 mmHg (systolic/diastolic). In a subsequent study that was not 
included in the meta-analysis, Taubert et al [9] showed that consuming as little as 30 mg of CF per 
day in 6g of dark chocolate for 18 weeks was sufficient to lower systolic blood pressure (SBP) by 
2.9 mmHg and diastolic blood pressure (DBP) by 1.9 mmHg. A more recent meta analysis by 
Hooper et al [10] also reported a net effect in favour in cocoa in the order of 6mmHg systolic and 
3mmHg diastolic. Although the potential antihypertensive effect of chocolate consumption is 
interesting, the high sugar and fat content of chocolate undermines its potential as a health 
enhancing food [11, 12]. 
Concern about delivering CF in a high sugar and high fat chocolate food matrix has led to 
investigations of the potential antihypertensive and other cardiometabolic health benefits of 
relatively low fat drinks enriched with CF. In a study which examined the acute effect of consuming 
a flavanol-rich cocoa beverage, Schroeter et al [13] demonstrated an increase in flow mediated  
dilatation of the brachial artery (FMD). Four studies have been conducted examining the longer-
term effects of consuming flavanol-rich cocoa beverages on cardiovascular health in various 
populations. In the first of these daily consumption of 446mg of cocoa flavanols by post-
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menopausal women for 6 weeks produced a significant improvement in arterial function but no 
change in BP compared to placebo [14]. In another study individuals with type 2 diabetes took 
963mg /day for a period of 30 days and also experienced improvements in endothelial function but 
not BP [15]. In a third study in which overweight or obese individuals consumed 902mg/day of 
flavanols for 12 weeks, there were improvements in endothelial function with modest yet significant 
reductions in BP (MAP reduced by 1.2 mmHg) [16]. The fourth study provided approximately 
900mg/day of CF to individuals with essential hypertension for 2 weeks [17]. Despite the similarity 
of this protocol to that by which Grassi et al [4] showed BP reductions with chocolate, and despite 
providing almost double the daily dose of CF, there was no change in BP although there was some 
improvement in endothelial function. The lack of BP change in three of these studies and the 
relatively small change in the other following chronic consumption of large doses of CF are 
inconsistent with the results seen in the meta-analysis [6] and subsequent study [9] with flavanol 
rich chocolate consumption. These findings suggest that the dose of CF alone does not determine 
the change in BP, however a number of differences in the design of these studies makes direct 
comparisons difficult. The studies that have been published to date examined different patient 
populations (healthy and hypertensive adults in chocolate based protocols and 
hypercholesterolaemic, overweight/obese and type 2 diabetic in non-chocolate protocols), and the 
type 2 diabetes study was confounded by participant medications. A further complication with 
comparison is a lack of consistency in the technique of BP assessment. Most studies have used 
seated clinic BP assessments with only three studies to date utilising the preferred technique of 
ambulatory blood pressure (ABP) monitoring  [3, 4, 18]. These three studies used the same protocol 
of a 15 day crossover study with dark chocolate (delivering approximately 500mg of CF) or white 
chocolate (CF free) in three separate subject groups including essential hypertensives and have 
reported the largest reductions in BP to date . With these factors in mind, a single study evaluating 
the potential BP lowering effects of CF in a homogenous patient population using the preferred 
method of ABP assessment and delivering the CF in a consistent food matrix was warranted. 
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Therefore, the primary aim of the present study was to determine the dose-response effect of CF 
delivered using a flavanol-rich cocoa beverage on 24-hour ambulatory mean arterial pressure 
(MAP) in an untreated borderline/mild hypertensive population. Secondary outcomes include clinic 
BP assessment and additional measures of 24-hour ABP. 
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Method 
Participants 
Male and post-menopausal female adults with high-normal BP or untreated mild hypertension (SBP 
130-160 mmHg or DBP 85-100 mmHg) were recruited by public advertisement. Participants were 
excluded if they had a known diagnosis of cardiovascular disease (or a history of cardiovascular or 
cerebrovascular incidents); Diabetes (Type 1 or Type 2) or were taking prescribed anti-diabetic 
medication; renal failure; were taking BP lowering medication or supplements that may influence 
BP (i.e. fish oil, liquorice, polyphenols) in the preceding 3 months, or were likely to do so during 
the study period; an intolerance to alkaloids (caffeine, theobromine) or dairy; were currently 
smoking or using nicotine replacement therapy; or had any other medical condition which may 
have influenced the outcome of the study. The study was approved by the Human Research Ethics 
Committee of the University of South Australia. Each participant provided written and informed 
consent prior to participation. Recruitment was carried out between February and August of 2007 
and the intervention was progressively conducted from April to October of 2007. 
 
Eligibility screening 
Potential participants were initially screened for eligibility by completing a health and lifestyle 
questionnaire and undertaking a seated clinic BP assessment. Participants with a seated BP between 
SBP 130-160 mmHg or DBP 85-100 mmHg were enrolled in the study. Enrolled participants 
returned to the clinic approximately one week later to have their BP measured under the same 
conditions as the initial screening to confirm the presence of high-normal BP or mild hypertension. 
If they requalified (i.e. SBP 130-160 mmHg or DBP 85-100 mmHg), they commenced the study 
protocol. If their BP fell outside these limits they were invited to return for an additional qualifying 
BP assessment. Participants with screening BP consistently above thresholds for BP (i.e. diastolic > 
100 mmHg; systolic > 160 mmHg) were referred to their GP and not entered into the study. 
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Protocol outline 
Participants were block-matched by the minimisation convention [19] on BP, gender, age and BMI 
into four treatment groups which were randomised to consume reconstituted cocoa beverages 
containing 33, 372, 712 or 1052 mg/d of CF for 6 weeks in a double-blind, parallel comparison. 
Randomisation of groups was undertaken independently of group minimisation procedure by 
separate staff members of the research centre not otherwise involved with the trial. Trial 
investigators remained blinded to treatment allocation until after the completion of data analysis. 
Participants then had body weight assessed and underwent seated clinic BP and 24 hour ABP 
assessments at baseline and were then required to consume a cocoa drink daily for the next 6 weeks. 
Seated clinic BP and 24 hour ABP assessments were repeated after 3 and 6 weeks (Table 2). 
 
Cocoa supplements 
The cocoa drinks were prepared by participants mixing the contents of three cocoa beverage sachets 
with  300 mL of water each morning and drinking 30 minutes prior to breakfast. The cocoa flavanol 
composition of the cocoa beverages are provided in Table 1. Sachets (dry powder – 58g net) were 
matched for micro and macro nutrients including total energy (mean ~ 910 kJ); saturated fat (mean 
~ 1.4g); sugar (approx. mean ~ 17.5g); caffeine (mean ~ 43mg); and theobromine (mean ~ 430mg). 
On all testing days (at 3 and six weeks), volunteers were instructed not to consume their cocoa 
beverage until after testing was completed to eliminate any acute effects of cocoa consumption. All 
empty sachets were returned at 3 and 6 weeks to monitor compliance. Participants were instructed 
to report any signs or symptoms of ill health immediately to the researchers and any action that was 
taken (e.g. medication) to identify any potential adverse effect of the intervention. In addition to this 
participants were specifically asked at each visit whether any signs or symptoms of ill health had 
been experienced. All reported events were documented by the researchers in each participant’s 
case report form. 
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Blood pressure monitoring 
Seated clinic BP was assessed after sitting quietly for at least 5 min using an automated 
oscillometric BP monitor (HDI/Pulsewave CR-2000 Cardiovascular Profiler, Hypertension 
Diagnostics Inc, Eagan, MN) in accordance with the procedures outlined by the Joint National 
Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (VII): 
US Dept of Health and Human Services [20]. Four consecutive BP readings were taken at 1 min 
intervals by a single observer. The first reading was discarded and an average of the remaining 
measurements was taken to determine eligibility for study entry. 
 
For assessment of 24 hour Ambulatory Blood Pressure (ABP), volunteers were fitted with a 
SpaceLabs ambulatory BP monitor (Model 90217, SpaceLabs Medical, Florida, USA) for 24 hours. 
An appropriately sized cuff was placed firmly around the upper non-dominant arm, centred over the 
brachial artery, with the monitor worn on a waist strap; ABP measurements were recorded at 15 
minute intervals excepting from 11 pm – 7am (30 minute intervals). The cuff and monitor was only 
removed briefly for bathing and remained in place at all other times during the 24 hour recording 
period. Assessments at baseline, 3 and 6 weeks were carried out on the same day of the week using 
the same monitor, cuff size and arm. Participants were required to maintain an activity diary during 
each 24 hour ABP period to enable BP values to be related to activities. 24 hour ABP recordings 
were used to determine daytime (7am – 11pm), night-time (11pm -7am) and 24-hour averages for 
MAP, SBP, DBP and heart rate (HR). 
 
Diet and lifestyle requirements 
Volunteers were asked to maintain their normal physical activity patterns and were provided with a 
list of dietary exclusions to ensure a low-flavanol diet for 1 week prior to and during the study 
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period. Given the energy content of the beverages (~900 kJ), volunteers were advised on 
appropriate diet substitutions to avoid increasing total energy intake. To monitor compliance with 
this request body weight was measured at each clinic visit. 
 
Statistical analysis 
It was estimated that a sample size of 12 subjects per arm would have at least 80% power to detect a 
statistically significant difference in reduction in MAP between the four treatment groups (allowing 
for multiple comparisons) using an ANOVA at the 0.05 significance level. The estimates were 
based upon the assumption of a linear dose response effect achieving a 5mmHg change in 24 hour 
MAP with the highest dose and a standard deviation of 4mmHg as indicated by unpublished pilot 
data. These estimates are supported by the previously reported ABP results with CF consumption 
(3, 4, 18). 
Baseline characteristics were compared between groups by one-way analysis of variance 
(ANOVA). Comparison of changes in ABP between treatment groups (i.e. CF dose) across time 
(i.e. 3 and 6 week assessments) was made using repeated measures analysis of covariance 
(ANCOVA) using baseline ABP as the covariate. Where ANCOVA showed a statistically 
significant main effect, post-hoc comparisons (Tukey’s HSD) were conducted to identify 
differences between means. To optimise the analysis of dose effects on ABP, a nested ANOVA 
design was used to examine changes in ABP from baseline by 3 and 6 weeks with time (i.e. weeks 3 
and 6) nested in dose. Comparison of changes in HR between treatment groups across time was 
made using repeated measures ANOVA. Statistical significance was set at p<0.05. All data are 
presented as mean ± SEM. 
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Results 
Participant flow is provided in Figure 1. In total, 53 volunteers completed the study. One volunteer 
was excluded due to mild persistent (>3 day) gastric symptoms that may have been related to the 
test beverage. No other adverse events related to the study were reported. Five volunteers withdrew 
during the study due to personal circumstances unrelated to the study. One volunteer was excluded 
from the analysis due to non-compliance to the study protocol, leaving 52 volunteers, or n=12-14 
volunteers per arm. Trial withdrawals and exclusions did slightly impact upon the success of the 
minimisation process on the matching of groups for the stated baseline parameters as can be seen in 
Table 1. However, no significant between group differences were seen for the blocking parameters 
including age (p=0.45), BMI (p=0.28), and BP (Systolic p=0.86; Diastolic p=0.45). Compliance 
with consumption of cocoa supplements was greater than 98% in all groups. Body mass did not 
change during the intervention (p = 0.48 for treatment x time). 
 
SBP, DBP, MAP or HR for 24-hour, night, day, and seated clinic measurements for each treatment 
group are provided in Tables 2-5. There were no dose x time interactions for seated clinic BP, but a 
significant time effect for SBP (p=0.02) and MAP p=0.01) was evident. However, there were 
significant dose x time effects for 24 hour MAP (p=0.047) and overnight HR (p = 0.041) assessed 
by ABP monitoring. ANCOVA of the change from baseline (week 0) to weeks 3 and 6 (with 
baseline values as a covariate) revealed a significant effect of dose on 24-hour ambulatory SBP 
(p=0.019), DBP (p=0.017) and MAP (p=0.008) and night ambulatory SBP (p=0.0006), DBP 
(p=0.005) and HR (p=0.043). 
 
Nested analysis (time nested in dose) revealed significant dose effects for 24 hour MAP (p=0.0004), 
SBP (0.001) and DBP (p=0.002); night time MAP (p=0.01; Fig 3) and SBP (p=0.003) and day time 
MAP (p=0.02; Fig 3) and SBP (p=0.02). Post hoc analysis showed that for the 1052 mg flavanol 
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dose, the reductions in for 24 hour MAP (p<0.001), SBP (p<0.02) and DBP (p<0.04) were 
significantly different from all other doses (refer Figure 2). There were no significant effects on HR. 
Figure 3 displays a consistent reduction in day and night ABP to that seen over the full 24 hours, 
with significant effects observed at a CF level of 1052 mg/d. 
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Discussion 
The principal finding of the current study was that the regular consumption of flavanol-rich 
reconstituted cocoa beverages reduced BP in untreated patients with borderline/mild hypertension. 
This antihypertensive effect was only evident at the highest dose of 1052 mg flavanols/day, with 
doses up to and including 712 mg/day failing to provide any significant reduction in BP in this 
study. This is the first study to directly compare the efficacy of differing dose levels of isolated CF. 
The doses used were based upon the range of CF levels that have been previously reported to lower 
BP. These findings suggest that BP can be lowered through the regular consumption of flavanol-
rich cocoa beverages, though higher levels of CF may be required than has been observed with 
consumption of chocolate based CF rich products. Although this study provided the highest dose of 
CF to date the lack of effect on BP with lower doses is supported by previous studies using a non-
chocolate food matrix. Whilst there was no evidence of a dose response effect over the doses tested 
in this trial, it may be the case that the highest dose in this study is on the lower end of a dose 
response curve with this type of CF product. Additionally, the maximum potential effect on BP is 
yet to be determined. 
 
Four previous studies have investigated the longer-term effects of consuming flavanol-rich cocoa 
beverages on BP [14-16] using beverages providing daily flavanol doses ranging from 446 – 964 
mg. Of these studies only one demonstrated a reduction in BP and this was a study which provided 
one of the highest doses of flavanols (902 mg/day). The finding of this study is in agreement with 
the outcome of the current study which demonstrated that a high daily flavanol dose is required in 
order to achieve a reduction in BP. However, these findings are in contrast with those which have 
examined the BP lowering effects of cocoa flavanols delivered in a chocolate food matrix where 
antihypertensive effects have been demonstrated with flavanol doses which were reported to be 
significantly lower than the levels used in the studies with cocoa beverages. A recent meta-analysis 
[9] which examined the antihypertensive effects of flavanol-rich chocolate found that daily 
 13
consumption of chocolate providing relatively modest doses of cocoa flavanols and procyanidins 
ranging from 246 mg to 500 mg provided significant reductions in BP. Subsequently, Taubert et al 
[9] showed that consuming as little as 30 mg of cocoa polyphenols per day in dark chocolate for 18 
weeks was sufficient to lower systolic blood pressure (SBP) by 2.9 mmHg and diastolic blood 
pressure (DBP) by 1.9 mmHg. This latter flavanol dose is similar to the lowest flavanol dose 
provided in the current study where no effect on BP was observed. Thus, it appears there may be a 
discrepancy in the effective dose of flavanols when delivered in a chocolate matrix compared to a 
beverage mix. A previous bioavailability study showed that there was no difference in the acute 
increases in plasma or urinary concentrations of flavanols following consumption of chocolate or 
dry cocoa containing the same quantities of flavanols [21], and similar bioavailability of cocoa 
flavanols from chocolate and other sources is also supported by comparisons from other studies [1, 
13, 21]. There has been some debate over the potential for the addition of milk protein to cocoa 
products to reduce flavanol bioavailability [22] and this would potentially impact on efficacy when 
consumed in milk drinks. However, other recent studies have not supported any effect of milk on 
reducing flavanol bioavailability [22-24]. 
 
A noteworthy protocol consideration when comparing the studies using flavanol-rich chocolate and 
flavanol-rich beverages are the degree of placebo control and blinding. Studies using chocolate have 
typically used a flavanol-poor white chocolate placebo which limits subject blinding and is not 
matched for all potentially bioactive nutrients including methylxanthines (3-4, 9). The use of 
flavanol-rich cocoa beverages allows close matching of placebo beverage nutrient composition as 
well as close matching for colour and flavour to facilitate a double blinded protocol (13-16).  
Muniyuppa et al (17) propose that the discrepancy between the results seen with dark chocolate and 
flavanol-rich cocoa beverages may be entirely due to these factors. The robust placebo control and 
blinding used in the present study combined with ABP monitoring provides a superior assessment 
of the anti-hypertensive potential of CF to those conducted previously. 
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The mechanism by which CF reduce BP has been largely attributed to their capacity to improve 
endothelial dilatory function [8, 25]. A number of studies have demonstrated that the regular intake 
of cocoa flavanols can improve endothelium-mediated vascular dilatory function, with these 
improvements being associated with an increased bioavailability of nitric oxide (NO) [2, 4, 25, 26, 
28]. Recently Taubert et al [9] established a direct relationship which suggested that the BP 
lowering effects of cocoa flavanols were mediated by improved NO availability when they found a 
statistically significant correlation between the magnitude of reduction in BP and the magnitude of 
increase in S-nitrosoglutathione (a marker of NO availability) following 18weeks of consuming 
chocolate containing cocoa flavanols. However, some studies have demonstrated improvements in 
vascular dilatory function independently of changes in BP, suggesting that other mechanisms might 
also contribute to the antihypertensive effect. Two recent studies [14, 15] reported a sustained (non-
acute) improvement in markers of endothelium-mediated dilatory function without concurrent 
changes to BP, while a third study [16] conducted in our laboratory showed improvement in both 
parameters but only a modest reduction was seen in BP while endothelium-mediated dilatory 
function improved by approximately 40%.  
 
The lack of a demonstrable effect of cocoa consumption on seated clinic BP in the present study 
may also reflect the relative lack of sensitivity of this technique compared with ABP monitoring. 
Seated clinic BP reduced with time independently of flavanol dose, reflecting a habituation effect 
(regression to the mean) which most likely masked any treatment effect on BP. An habituation 
effect was not evident with ABP monitoring. In a previous study, we were able to demonstrate a 
statistically significant reduction in BP with clinic assessments [16], but the BP assessment 
protocol in that study was different from that used in the current study with clinic BP measured 
while participants were supine after a longer pre-assessment rest period. Additionally for the 
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previous study patients with elevated BP were not specifically recruited which may have reduced 
the likelihood of a ‘white coat’ hypertensive effect masking any effect of the cocoa supplement. 
 
A key concern with the consumption of bioactive nutrients for health benefits is the question of 
potential adverse effects of the other ingredients. In the case of cocoa flavanols this concern is 
particularly associated with the high energy and saturated fat content of chocolate. According to 
HPLC analysis of flavanol content of various food types, to achieve the effective dose of flavanol 
seen in this study (1052mg) would require the daily consumption of 210g of standard dark 
chocolate or approximately double this amount of milk chocolate  [29]. Given that 210 grams of 
dark chocolate provides in the order of 4700Kj and 35g of saturated fat a net health effect may be 
questionable [30]. This is in contrast to the 914kJ and 1.4g of saturated fat provided by the 
beverage used in this trial. However, depending upon the underlying causes of the previously 
discussed discrepancy between the effect of chocolate and flavanal rich cocoa beverages on BP, 
this comparison may not prove valid. It should be noted that the intention of this trial was not to 
evaluate the use of a flavanol rich beverage as a potential food supplement, but rather to determine 
the effect of various doses of cocoa flavanols on BP. 
 
Ideally the lowest dose would deliver 0mg of flavanol; however, this would be not possible with 
our cocoa based product without significantly altering the flavour and or consistency of the drink, 
thereby compromising the treatment blinding. Although Taubert et al [9] reported an 
antihypertensive effect of 30mg CF/day, this has only been seen with a white vs. dark chocolate 
protocol and not with a well matched control so interpretation of these data are subject to the 
limitations listed above. Moreover others have failed to show effects on BP of considerably higher 
doses of isolated CF [14, 15]. Other concerns regarding the 33mg dose results in the present study 
relate to the lower age and BMI and greater proportion of males in this group. While care was taken 
to avoid this in the blocking process, with the relatively small subject numbers per treatment arm 
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small numbers of participant attrition can disrupt this balance. It could be argued that this may 
reduce the potential responsiveness of the control group, however the lack of BP reduction seen at 
the two intermediate doses suggests this has not influenced the overall results. Additionally, the 
differences seen in BMI and age were not statistically significant and the most important variable 
(BP) remained well matched across the four groups. The final limitation was the lack of explicit 
assessment of the effectiveness of the blinding protocol. The close matching of the cocoa products 
implies successful blinding, however these results could have been strengthened by assessing this. 
 
In summary, this study provides the most robust assessment of the effects of cocoa flavanols on 
blood pressure to date. A significant antihypertensive effect of daily cocoa flavanol intake was 
observed at the highest dose of 1052mg flavanols/day with no BP lowering effect seen at the lower 
doses. This study supports the potential for cocoa flavanols to lower BP, but further research is 
required to determine the extent of antihypertensive benefit that can be achieved with different 
dietary sources and doses of flavanols in various cardiovascular pathologies. 
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Table 1: Flavanol composition (monomers and polymers/oligomers) of daily beverage for each 
dose group. 
 
Group No. 1 2 3 4
Total flavanol dose 33 372 712 1052
Epicatechin 0 69 138 208
Catechin 12 28 43 58
Other flavanols 20 275 530 785
(polymeric/oligomeric)  
Macronutrient   
Weight (g) 58 58 58 58
Energy (kJ) 904.5 907.9 911.2 914.6
Total fat (g) 2.6 2.6 2.6 2.6
Sat fat (g) 1.4 1.4 1.4 1.4
Total CHO (g) 31.0 31.2 31.5 31.8
Sugars (g) 17.3 17.4 17.6 17.7
Protein (g) 17.1 17.1 17.1 17.1
Caffeine (mg) 46.6 44.7 42.7 40.8
Theobromine (mg) 402.2 421.6 441.1 460.5
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Table 2: Baseline characteristics. (mean ± SEM). M/F = ratio male to female; BMI = body mass 
index. 
 
Group (mg flavanol/day) 33 mg 372 mg 712 mg 1052 mg 
N 14 12 13 13 
Age (years) 53.0 ± 6.7 56.2 ± 14.2 60.2 ± 13.7 56.8 ± 9.7 
M/F 10/4 7/5 8/5 7/6 
BMI (kg/m2) 33.7 ± 16.8 28.7 ± 5.5 26.9 ± 16.2 27.9 ± 5.0 
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Table 3: Systolic BP (mmHg) for 24 hour, night, day and seated clinic measurement in each 
treatment group (mg flavanol/day) at each assessment point (mean ± SD). 
 
Dose 
(mg) 
BP 
(mmHg) Week 0 Week 3 Week 6 ∆ week 3 ∆ week 6 
33 
 
N=14 
24hr 133.3 ± 11.6 132.5 ± 14.6 133.9 ± 13.8 -0.8 ± -5.6 0.6 ± 7.1
Night 117.1 ± 14.2 116.9 ± 15.3 118.6 ± 10.5 -0.2 ± 6.4 1.5 ± 8.6
Day 140.1 ± 11.2 140.0 ± 15.0 141.2 ± 15.7 -0.1 ± -7.1 1.1 ± 10.1
Clinic 145.4 ± 9.7 142.1 ± 10.5 143.3 ± 13.1 -3.3 ± -6.0 -2.1 ± -9.0
                       
372 
 
N=12 
24hr 133.1 ± 11.2 132.9 ± 13.3 133.4 ± 13.0 -0.2 ± -5.0 0.3 ± 6.5
Night 115.5 ± 12.3 115.6 ± 10.5 115.4 ± 13.7 0.1 ± 6.5 -0.1 ± -8.7
Day 141.1 ± 12.3 140.8 ± 15.1 142.5 ± 14.8 -0.3 ± -6.5 1.4 ± 6.9
Clinic 142.9 ± 10.5 142.0 ± 11.9 139.6 ± 9.0 -0.9 ± -9.0 -3.3 ± -7.9
                       
712 
 
N=13 
24hr 127.4 ± 7.6 127.9 ± 9.0 128.9 ± 8.3 0.5 ± 6.2 1.5 ± 5.9
Night 111.0 ± 9.7 113.1 ± 10.0 114.7 ± 10.7 2.1 ± 8.7 3.7 ± 5.5
Day 134.6 ± 7.6 134.4 ± 9.4 135.6 ± 8.0 -0.2 ± -5.5 1.0 ± 6.6
Clinic 143.0 ± 9.0 140.2 ± 10.4 140.0 ± 9.4 -2.8 ± -6.6 -3.0 ± -9.7
                 
1052 
 
N=13 
24hr 127.8 ± 9.4 121.0 ± 10.7 124.0 ± 10.7 -6.8 ± -5.9 -3.8 ± -5.5
Night 113.5 ± 11.8 106.8 ± 9.7 110.1 ± 7.3 -6.7 ± -8.0 -3.4 ± -8.0
Day 133.2 ± 9.4 127.4 ± 12.1 129.8 ± 13.5 -5.8 ± -5.2 -3.4 ± -7.3
Clinic 143.0 ± 8.0 139.8 ± 11.1 138.9 ± 13.5 -3.2 ± -3.1 -4.1 ± -12.1
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Table 4: Diastolic BP (mmHg) for 24 hour, night, day and seated clinic measurement in each 
treatment group (mg flavanol/day) at each assessment point (mean ± SD). 
 
Dose 
(mg) BP (mmHg) Week 0 Week 3 Week 6 ∆ week 3 ∆ week 6 
33 
 
N=14 
24hr 82.2 ± 7.1 81.6 ± 7.9 82.8 ± 7.9 -0.6 ± -3.4 0.6 ± 4.1 
Night 70.0 ± 8.6 69.7 ± 9.0 71.6 ± 6.4 -0.3 ± -5.6 1.6 ± 4.5 
Day 87.2 ± 6.4 86.7 ± 8.2 87.6 ± 9.0 -0.5 ± -4.5 0.4 ± 6.4 
Clinic 88.0 ± 6.0 87.7 ± 7.5 88.1 ± 7.9 -0.3 ± -3.7 0.1 ± 4.9 
                       
372 
 
N=12 
24hr 81.3 ± 8.7 80.6 ± 10.0 81.4 ± 10.0 -0.7 ± -2.8 0.1 ± 3.6 
Night 69.3 ± 7.6 69.1 ± 9.0 69.3 ± 8.7 -0.2 ± -4.5 0.0 ± 5.8 
Day 87.0 ± 10.0 86.1 ± 11.4 87.2 ± 11.1 -0.9 ± -3.5 0.2 ± 3.6 
Clinic 86.4 ± 7.6 85.9 ± 8.0 83.9 ± 9.7 -0.5 ± -5.2 -2.5 ± -5.8 
                       
712 
 
N=13 
24hr 78.3 ± 9.4 78.2 ± 9.4 79.1 ± 10.5 -0.1 ± -3.2 0.8 ± 2.5 
Night 66.9 ± 8.7 67.8 ± 10.5 69.6 ± 11.5 0.9 ± 5.4 2.7 ± 5.4 
Day 83.2 ± 10.1 82.6 ± 9.7 83.6 ± 10.5 -0.6 ± -3.2 0.4 ± 3.2 
Clinic 85.9 ± 9.4 84.4 ± 11.5 84.2 ± 10.1 -1.5 ± -5.8 -1.7 ± -5.0 
                 
1052 
 
N=13 
24hr 76.3 ± 9.0 72.5 ± 9.4 74.2 ± 8.7 -3.8 ± -3.6 -2.1 ± -3.2 
Night 66.0 ± 8.3 63.3 ± 8.3 65.0 ± 6.9 -2.7 ± -4.7 -1.0 ± -4.3 
Day 80.0 ± 9.4 76.5 ± 10.1 78.3 ± 9.4 -3.5 ± -3.2 -1.7 ± -4.7 
Clinic 83.2 ± 9.4 81.2 ± 10.8 81.2 ± 8.7 -2.0 ± -6.1 -2.0 ± -3.2 
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Table 5: Mean arterial pressure (mmHg) for 24 hour, night, day and seated clinic measurement in 
each treatment group (mg flavanol/day) at each assessment point (mean ± SD).  
 
 
Dose 
(mg) BP (mmHg) Week 0 Week 3 Week 6 ∆ week 3 ∆ week 6 
33 
 
N=14 
24hr 98.5 ± 8.2 97.8 ± 9.4 98.9 ± 9.4 -0.7 ± -3.4 0.4 ± 4.9 
Night 85.8 ± 9.4 85.3 ± 10.5 87.4 ± 7.1 -0.5 ± -5.2 1.6 ± 4.9 
Day 104.1 ± 7.5 103.5 ± 9.7 104.3 ± 10.5 -0.6 ± -4.5 0.2 ± 6.7 
Clinic 107.1 ± 6.7 105.9 ± 8.2 106.5 ± 9.4 -1.2 ± -3.4 -0.6 ± -4.9 
                       
372 
 
N=12 
24hr 98.3 ± 8.0 98.4 ± 9.7 98.9 ± 9.4 0.1 ± 3.5 0.6 ± 4.5 
Night 85.8 ± 8.3 85.8 ± 8.0 85.9 ± 8.7 0.0 ± 5.2 0.1 ± 6.0 
Day 104.0 ± 8.7 104.0 ± 11.4 105.1 ± 10.7 0.0 ± 4.8 1.1 ± 5.2 
Clinic 105.3 ± 6.9 104.6 ± 8.7 102.5 ± 8.7 -0.7 ± -5.5 -2.8 ± -4.1 
                       
712 
 
N=13 
24hr 95.4 ± 6.9 95.2 ± 7.2 96.0 ± 8.3 -0.2 ± -4.0 0.6 ± 3.6 
Night 82.6 ± 7.6 84.1 ± 8.3 85.8 ± 9.7 1.5 ± 6.9 3.2 ± 4.7 
Day 101.0 ± 6.5 99.9 ± 7.6 100.9 ± 7.9 -1.1 ± -4.0 -0.1 ± -4.0 
Clinic 105.0 ± 8.3 103.0 ± 9.7 102.8 ± 8.7 -2.0 ± -5.4 -2.2 ± -5.8 
                 
1052 
 
N=13 
24hr* 93.8 ± 6.9 89.2 ± 8.7 90.8 ± 7.2 -4.6 ± -4.0 -3.0 ± -3.2 
Night 82.8 ± 7.9 79.2 ± 7.6 80.8 ± 5.8 -3.6 ± -5.4 -2.0 ± -6.1 
Day 97.9 ± 7.2 93.8 ± 9.7 95.2 ± 8.7 -4.1 ± -4.0 -2.7 ± -4.7 
Clinic 103.1 ± 7.6 100.7 ± 9.7 100.4 ± 9.4 -2.4 ± -7.2 -2.7 ± -7.9 
 
* Significant dose x time interaction (p=0.047) 
 
 24
Table 6: Heart Rate (beats/min) for 24 hour, night, day and seated clinic measurement in each 
treatment group (mg flavanol/day) at each assessment point (mean ± SD). 
 
Dose 
(mg) BP (mmHg) Week 0 Week 3 Week 6 ∆ week 3 ∆ week 6 
33 
 
N=14 
24hr 68.1 ± 9.7 70.8 ± 10.5 70.6 ± 10.9 2.7 ± 5.2 2.5 ± 6.0 
Night 60.4 ± 8.6 62.4 ± 8.2 61.6 ± 10.1 2.0 ± 3.4 1.2 ± 4.9 
Day 71.5 ± 10.9 74.2 ± 12.0 74.4 ± 11.2 2.7 ± 6.4 2.9 ± 6.7 
Clinic 64.6 ± 13.1 65.0 ± 13.1 63.9 ± 12.3 0.4 ± 4.9 -0.7 ± -6.4 
                       
372 
 
N=12 
24hr 72.7 ± 10.4 72.5 ± 9.7 73.5 ± 10.4 -0.2 ± -2.4 0.8 ± 5.9 
Night 64.4 ± 10.7 64.3 ± 11.4 64.3 ± 9.7 -0.1 ± -3.8 -0.1 ± -5.9 
Day 76.3 ± 10.0 76.3 ± 9.4 77.9 ± 10.7 0.0 ± -3.5 1.6 ± 5.2 
Clinic 72.4 ± 14.2 70.0 ± 10.7 69.2 ± 11.1 -2.4 ± -6.6 -3.2 ± -6.6 
                       
712 
 
N=13 
24hr 68.6 ± 8.7 70.4 ± 10.5 69.7 ± 8.3 1.8 ± 4.0 1.1 ± 3.2 
Night 61.2 ± 7.9 63.1 ± 10.8 61.9 ± 7.2 1.9 ± 4.7 0.7 ± 2.5 
Day 71.9 ± 9.7 73.4 ± 10.8 73.2 ± 9.0 1.5 ± 4.3 1.3 ± 4.7 
Clinic 64.8 ± 8.7 65.9 ± 9.0 64.6 ± 7.6 1.1 ± 6.1 -0.2 ± -4.3 
                 
1052 
 
N=13 
24hr 74.1 ± 5.4 74.3 ± 9.0 76.9 ± 9.4 0.2 ± 7.2 2.8 ± 7.2 
Night 67.3 ± 6.5 66.3 ± 7.6 70.8 ± 7.2 -1.0 ± -5.0 3.5 ± 4.3 
Day 77.0 ± 6.1 78.1 ± 10.5 79.8 ± 10.5 1.1 ± 9.4 2.8 ± 9.0 
Clinic 74.3 ± 7.2 74.1 ± 11.9 71.8 ± 10.8 -0.2 ± -9.7 -2.5 ± -9.4 
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Table 7: Summary of study 
What is known about this topic? What this study adds 
 
• Consumption of cocoa rich chocolate has 
been shown to lower blood pressure (BP) 
A meta-analysis of several intervention trials has 
demonstrated a BP lowering effect of cocoa rich 
dark chocolate compared to cocoa free white 
chocolate. 
• Cocoa flavanols (CF)improve endothelial 
function 
Isolated CF and cocoa solids have been shown to 
enhance endothelial vasodilatation in the same 
manner as cocoa rich chocolate. 
• Lack evidence for effect of CF on BP 
Chronic consumption of isolated cocoa solids 
delivering CF doses in excess of those provided in 
chocolate have not lowered BP. 
 
• Robust evaluation of effects of isolated 
cocoa solids on BP 
Dose response evaluation of CF on ambulatory 
BP in borderline/mild hypertensives.  
• The study identifies a threshold dose  for 
cocoa flavanols 
Only the highest dose of CF (1052mg/day) 
lowered BP. This would account for lack of effect 
on BP with sub-threshold doses of CF in previous 
studies. 
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Figure 1: Consort diagram * withdrawn for personal or health reasons not related to study protocol; 
** excluded due to gastric symptoms possibly related to cocoa beverage; ***excluded due to non-
compliance to study protocol (deliberate weight loss during intervention period). 
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Figure 2: Dose-related effects of cocoa flavanols on 24 hour ambulatory blood pressure. 
Values represent means ± SEM of changes from baseline (average of changes to 3 and 6 weeks).  
*Significantly different from all other doses by nested analysis (p<0.001). 
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Figure 3: Dose-related effects of cocoa flavanols on daytime and overnight ambulatory blood 
pressures. Values represent means ± SEM of changes from baseline (average of changes to 3 and 6 
weeks).   
 
 
 



